GlassScriptPhysician profile
Philip W Laird
NPI 1548416399
$8,162.57
in general payments reported to CMS, 2019-2025
25 companies · $298 in 2025
The $298 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,490 · 2020: $693 · 2021: $1,225 · 2022: $2,171 · 2023: $1,305 · 2024: $981 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,584.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $2,996.54 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $895.48 | 2019-2024 | Eylea Hd, Eylea |
| Dutch Ophthalmic, USA | $492.14 | 2020-2024 | Tissueblue, Eva, Combined Machine |
| Alimera Sciences, INC. | $451.22 | 2020-2024 | Iluvien, Yutiq |
| Genentech USA, INC. | $435.62 | 2021-2025 | Vabysmo, Susvimo |
| Apellis Pharmaceuticals, INC. | $417.27 | 2023-2024 | Syfovre |
| Eyepoint US, INC. | $387.66 | 2019-2022 | |
| Astellas Pharma US INC | $343.35 | 2023-2025 | Izervay |
| Omeros Corporation | $234.27 | 2019-2021 | |
| Abbvie INC. | $230.46 | 2022-2025 | |
| Allergan, INC. | $208.12 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $156.51 | 2019 | |
| Kala Pharmaceuticals, INC. | $145.42 | 2019 | |
| Rayner Intraocular Lenses Limited | $124.99 | 2024 | Rayone Emv, Rayone Spheric, Rayone Aspheric |
| Regeneron Pharmaceuticals, INC. | $108.19 | 2024 | Eylea Hd |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $106.05 | 2019 | |
| Ivantis, INC | $99.19 | 2020 | |
| Ani Pharmaceuticals, INC. | $97.94 | 2024-2025 | Yutiq, Purified Cortrophin Gel |
| Hoffmann-La Roche Limited | $79.54 | 2019 | |
| Sun Pharmaceutical Industries INC. | $43.23 | 2019 | |
| Bausch & Lomb Americas INC. | $33.68 | 2023-2025 | Xipere |
| Alcon Vision LLC | $23.93 | 2023 | Constellation |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $21.97 | 2020 | |
| Notal Vision, INC. | $16.15 | 2024 | Foresee Home |
| Biogen, INC. | $13.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$56,523.50 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Laird listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.